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abstract: In view of the global burden of subfertility, efforts are required to make assisted reproduction more effective, less burden-
some and more equally accessible. New reproductive technologies are frequently introduced in clinical practice without a sound evaluation of
their efficacy, effectiveness and/or safety. Safety issues in this context refer both to patients (mostly women) undergoing the relevant medical
procedures, and to the health of children born as a result. Responsible innovation requires making potentially risky reproductive technologies
the subject of research, ideally proceeding through the steps of preclinical investigations, clinical trials and (long-term) follow-up studies. The
European Society of Human Reproduction and Embryology is especially equipped to take the lead here.
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Introduction
More than 4 million children have been born after IVF, mostly to parents
who would otherwise not have been able to enjoy this fulfilment of a
deeply held human desire. This would not have been possible but for
the fruits of constant innovation within the highly dynamic field of medi-
cally assisted reproduction. Contrary to the impression that may arise
from media hype and ensuing debates, assisted reproduction is funda-
mentally a morally sound, not a morally problematic practice.
This also means that there is a moral imperative for further inno-
vation: to make assisted reproduction more effective, less burdensome
for the women involved and more widely accessible to those who
without this technology would not be able to have children or those
who, because of a high risk of having a child affected with a genetic
disease, would otherwise not be able to reproduce with confidence.
Innovative treatment or
research?
There are two forms of innovation in medicine (Eaton and Kennedy,
2007): formal ‘medical research’ on the one hand and ‘innovative
treatment’ or ‘clinical innovation’ on the other. The latter is what clin-
icians do when they try something new that has not yet been
thoroughly tested in a research setting. For instance a new surgical
technique or the off-label use of certain drugs. This form of innovation
circumvents the strict requirements and rules of formal research
(Margo, 2001). As a result, patients may not always be aware of the
experimental nature of proposed innovative treatment, nor about
possible risks. Furthermore, although innovative treatments often
lead to publications, these are mostly not of the kind that will yield
robust data about the efficacy and safety of the relevant procedures.
They often refer to series of patients that are compared with historical
cohorts using a diversity of clinical outcome measures rather than
being formally structured to include blinding, randomization and
clear prospectively designed endpoints. As a consequence, insuffi-
ciently validated treatments may find their way to regular practice.
The positive side of having this option of innovative treatment,
some will argue, is that it allows innovations to become available for
helping patients sooner than would have been possible if the lengthy
and arduous route of regulated research were chosen. A good illus-
tration is the off-label use of anti-retroviral and anti-infective drugs
that turned out to be life-saving for thousands of patients who other-
wise would have died of AIDS (Wilkes and Johns, 2008). In the light of
such examples, there is an understandable feeling among many prac-
titioners that the research route stifles innovation. On the other
hand, illustrations can also be given of cases where procedures were
introduced into clinical care without proper testing that later on
turned out to be ineffective or harmful. In the context of medically
assisted reproduction the premature introduction of preimplantation
genetic screening (PGS) for aneuploidy is a good example. This was
introduced as regular care in many clinics, but in subsequent trials
turned out not to do what it was thought to do, with the possible
implication of reducing rather than enhancing chances of successful
pregnancy (Geraedts and De Wert, 2009). On the initiative of the
Pre-implantation Genetic Diagnosis (PGD) Consortium of the
European Society of Human Reproduction and Embryology (ESHRE),
PGS is now in the process of being re-evaluated in a different form
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(polar body biopsy and analysis of all chromosomes) in a proper
research setting (Geraedts et al., 2010; Harper et al., 2010).
According to authoritative documents, including the Helsinki
declaration (World Medical Association, 2008) and the American
Belmont report (National Commission, 1979), innovative treatment
ought to be made the object of research as soon as this is practically
possible. An obvious problem is the difficulty of distinguishing between
innovative treatment and mere adaptations of clinical management
(Reitsma and Moreno, 2005). In cases such as the use of new instru-
ments, or a slightly different surgical technique, it would be absurd and
impossible to require that everything new should be introduced
through the route of research. This is why the Belmont report uses
the qualifiers ‘radically new procedures’ and ‘major innovations’.
Clearly, the distinction between what is and is not radically new,
and between major and minor will remain a matter of opinion.
What about changes in culture media used in IVF laboratories? Most
practitioners would seem to feel that these are adaptive practices
rather than major innovations. This may depend on the nature of
the substances used and what is already known about their features
and safety profile from use in other contexts.
However, let us focus on what are clearly major innovations in the
field of medically assisted reproduction. The historical record shows
that several such innovations have been introduced in clinical practice
without much preclinical research into their effectiveness and safety.
One may think here of cryopreservation of embryos, ICSI, ooplasm
transfer and most recently oocyte vitrification. Is there a problem
with this? Has not the history of IVF and related technologies been
a continuing success story, leading to reassuringly healthy children in
the vast majority of cases? No serious safety problems have
emerged, apart from the adverse health effects of multiple pregnancies
(especially higher order multiples), something that the field is now
trying to prevent. However, recent reviews have suggested that single-
ton IVF-children are also at a higher risk of adverse pregnancy out-
comes including preterm delivery and a low-birthweight (Halliday,
2007; McDonald et al., 2009). The cause of this is unknown and
may be related to one or more of the various technical variables of
IVF, or to factors related to subfertility per se, or to both. A specific
cause for concern is that certain rare imprinting disorders such as
Beckwith–Wiedemann Syndrome have been found to be significantly
increased after IVF (Amor and Halliday, 2008; Owen and Segars,
2009). Furthermore, epigenetic modifications may perhaps put IVF
children at a higher risk not only of pregnancy complications and
specific birth defects, but also of more subtle effects on their long-
term health, including an increased susceptibility for developing
cancer and other common diseases (Niemitz and Feinberg, 2004;
Katari et al., 2009). The precise implications of this are still unclear.
Some commentators have suggested that we may be looking at the
tip of an ‘epigenetic iceberg’ or sitting on a ticking ‘developmental
time bomb’ (Maher et al., 2003; Grace and Sinclair, 2009). Others
will find those images far too dramatic and unnecessarily alarming.
The case for responsible
innovation
Whoever is right here, these concerns remind us of the special nature
of IVF: a procedure with consequences not just for those wanting to
be treated. Of course, the first responsibility of fertility professionals
is towards their patients. But as stated by ESHRE’s Task Force
Ethics & Law, the causal contribution of fertility professionals to the
establishment of pregnancy makes them co-responsible for the
welfare of children born as a result (Pennings et al., 2007). Moreover,
given the interest of society in the good health of future generations,
possible public health effects should also be taken into account
(Young, 2001; Sinclair et al., 2007). If a possible link between IVF
and epigenetic modification leads to a small increase in the relative
risk for cancer or other common diseases, the public health impact
may be considerable. The field is already taking this perspective with
regard to advising patients about preconceptional life style issues
(Dondorp et al., 2010). But if we are concerned about the lower birth-
weight of children of women who continue to smoke during preg-
nancy, then certainly we should also be concerned about the lower
birthweight found in IVF singletons.
In the light of these interests and responsibilities, a strong case can
be made for a more ambitious approach to innovation in medically
assisted reproduction than the field has generally shown in the past.
We need to know more about the health impact of new reproductive
technologies for all interested parties (women, children, society)
before accepting them as part of the standard toolbox.
Animal research
Ideally, innovation should start with preclinical research in animal
models designed not only to test feasibility, but also to investigate
the safety of a new technology (Pennings et al., 2007). Obviously,
much experience has been gathered from the use of reproductive
technologies in farm animals, showing that these technologies
may contribute to differential pregnancy outcomes (Lonergan, 2007;
Sinclair, 2008).
Where possible and useful, animal safety studies are crucial in that
they allow the study of multigenerational effects in a shorter time span.
No such studies were done prior to the introduction of ICSI, not only
because testing in animal models was too readily assumed to be tech-
nically impossible, but also because of the immediate success of the
new approach, leading to the birth of healthy children (Te Velde
et al., 1998; Hewitson, 2004). In the case of oocyte freezing, systema-
tic preclinical studies in animals were undertaken, but only after early
clinical applications led to high failure rates caused by chromosomal
damage (Oktay et al., 1998).
A case can be made for considering the possibility of safety studies
in primate models as these are more close to humans (Bavister, 2004;
Hewitson, 2004). In a recent interview John Biggers recounts an early
debate at an NIH meeting about the possible funding of clinical IVF
research in the USA (Biggers and Racowsky, 2008; Biggers, 2010).
At this meeting in the late 70s, the notion was discussed that
women should not be exposed to IVF treatment until the safety of
the methods had been worked out using monkeys. Although this pro-
posal was supported by some of his most influential colleagues, Biggers
felt it would take too long and be too expensive. ‘I felt that we already
had enough information to proceed with caution. The committee
accepted my point of view’ (Biggers and Racowsky, 2008). An oppos-
ing view, stressing the need for prior animal research, was one of the
reasons why the British Medical Research Council (MRC) had rejected
the application of Edwards and Steptoe a few years earlier (Johnson
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et al., 2010). As a consequence of that decision the work leading to
the birth of Louise Brown proceeded with funding from private
donors and in the form of innovative treatment rather than through
the formal research approach that the rejected application had
aimed at. Looking back at these debates and given the uncertainties
that the field still faces over long-term safety effects, one may ask
whether a useful third option might have been a multi-track approach
in which parallel to ‘proceeding with caution’, safety studies in
monkeys were also conducted. As the life span of appropriate
primate models (old world monkeys) is considerable shorter than
that of humans, it is conceivable that this would by now have begun
to yield some of the insights we currently expect from long-term,
ideally also multigenerational follow-up in children born after IVF. Of
course the costs of such research are huge, and primate research is
an even more sensitive issue in society than animal research using
mice and rats. But whenever a case can be made for the usefulness
of such parallel long-term safety studies in primates, these consider-
ations need not be categorically prohibiting.
Embryo research
Even when preceded by reassuring animal studies, the step to first
clinical experiments inevitably involves a leap of faith. Indeed, the
question is how much animal research is enough and when it is safe
to move on to human application. In this connection, research using
human preimplantation embryos may be an important intermediate
step (Pennings et al., 2007). Quite some time ago several commenta-
tors referred to cryopreservation and in vitro maturation of oocytes as
examples of new technologies where preclinical embryo research
might be useful (Health Council of the Netherlands, 1998; De
Rycke et al., 2002). This would involve creating embryos from
oocytes having undergone the relevant manipulations and using the
resulting embryos for (additional) safety studies, focusing on possible
effects on developmental processes and epigenetic mechanisms.
Underlining the importance of this type of research, Anne McLaren
once compared the direct clinical introduction of innovative technol-
ogies in assisted reproduction with ‘making the first test of a new
aircraft-guidance system on a crowded Boeing 747’ (McLaren, 1989).
As this sounds quite sensible, why is it that in cases where preclinal
embryo research might have been possible, this step is usually
skipped? Part of the explanation is probably that many centres do
not like the idea of further delaying the introduction of a new technol-
ogy that they find promising and feel confident about, especially if
there is competition between groups. But legislative limits also play
a role. The categorical prohibition of creating embryos for purposes
of research in the European Convention on Human Rights and Biome-
dicine and in the law of many European countries means that even if
centres want to conduct the relevant type of safety studies in
embryos, they are legally not allowed to do so. It is ironic that
society gives so much protection to the human embryo that as a con-
sequence women and children are put at greater risk (Health Council
of the Netherlands, 1998). The reasoning behind the prohibition is dif-
ficult to sustain given the broad consensus about the relatively low
moral status of the preimplantation embryo presupposed in the justi-
fication of IVF itself (Devolder, 2005; Dondorp and De Wert, 2007).
Indeed, the question is not whether human embryos may be created
for instrumental purposes, but what purposes are important enough
to justify doing so and under what further conditions. Clearly, research
involving the creation of human embryos can only be acceptable if the
necessary donor-oocytes are obtained in a morally responsible way,
including stimulation protocols that minimize the risks for the
women involved (De Wert and Mummery, 2003).
The adverse effect that embryo protection legislation may have on
the scope for responsible innovation has become clear in the case of
Italy. Here the intention of the Legislature has been to rule out the
instrumental use of human embryos in the context of IVF. In order
to avoid embryos becoming surplus, the Italian law of 2004 obliged
practitioners to transfer all embryos to the womb in the same cycle
in which they were created (Boggio and Corbellini, 2009). One
effect of this ruling was the turn towards cryopreservation of surplus
oocytes through slow freezing and vitrification (Ubaldi et al., 2010).
This has given a strong impetus to the further development of these
techniques and some Italian clinicians argue that IVF-practice in their
country has improved as a result. But the point here is that legislation
taking the supposedly moral high ground of absolute embryo protec-
tion may in fact be morally problematic if it leads to new techniques
being prematurely introduced into clinical practice. Responsible inno-
vation is not just a responsibility of clinicians, but requires that legis-
lators and policy-makers take their share as well (Dondorp and De
Wert, 2007).
It seems that by now the rapid dissemination of oocyte vitrification
has rendered the idea of preclinical embryo research a superseded
proposition. But here again a case can perhaps be made for a parallel
or multi-track approach. Accepting clinical introduction as a fact need
not mean that there can be no further role for trying to learn more
about the safety of the procedure by doing research in human
embryos. Embryo research can possibly also be useful as part of an
effort to find out if certain elements of current IVF-treatment may
perhaps contribute to the findings about a higher risk of adverse peri-
natal outcomes in singletons.
Clinical studies
When, ideally after sufficiently reassuring animal and embryo studies,
new technologies are introduced into clinical practice, it is of utmost
importance that this is done in a way aimed at prospectively collecting
uniform data about effectiveness and safety. The pioneering Brussels
centre has made a laudable and important contribution to this with
regard to ICSI, and some other centres worldwide have done the
same. But it would have helped in generating the large database that
is needed if all centres starting with ICSI had taken their share in
this. There is a tendency that centres simply copy successful inno-
vations without assuming the responsibility to also do their part in
the research aimed at evaluating clinical outcomes.
Large multicenter prospective follow-up studies are needed in
order to evaluate not just short-term, but also medium- and long-term
outcomes of several forms of assisted reproduction, stretching into
and beyond reproductive maturity. Protocols for these studies
should be carefully and uniformly designed in order to allow them
also to pick up more subtle health effects. Whatever the reasons
and possible justifications for taking shortcuts when it comes to
doing preclinical safety research, there can be no excuse for not
trying to find out about the effects of new forms of treatment, also
in the long run. The recent debate about possible epigenetic effects
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that may be associated with diseases later in life should give the field as
a whole a strong motive for coordinated efforts to ensure that long-
term follow-up studies are a central part of its innovation strategy
for the future. This of course presupposes the active participation of
IVF families and requires the continuing consent first of the parents
but then also of the maturing child as it grows into adulthood.
Implementation
It is one thing to refer to an ideal model for responsible innovation, it is
quite another to implement this in practice. Although it is clear that
individual practitioners share in the responsibility of the field to get
this off the ground, their powers are limited. They are subject to
the rat race between innovating centres that leaves little room to
take time for additional research. And if they themselves would
prefer to take a more cautious route to innovation, it may be difficult
to find funding for anything beyond feasibility studies. They may also be
under strong pressure from patients to go ahead with innovations if
expected benefits were already set out in the press. An imaginable
response is to try to shift all responsibility to the patients under the
heading of ‘informed consent’. If patients agree to be treated with
an innovative technique, being warned that not much is yet known
about possible adverse effects, then what is the problem? The
problem is of course that clinicians remain responsible for what they
do, not just with regard to consenting patients but also in view of
the welfare of any children that will be born as a result and with
regard to the interests of society at large.
A role for ESHRE?
To a large extent, responsible innovation will remain a pious ideal if
this is not actively supported by professional societies and regulators
where they exist. The importance of this is clear if we do not
just look at examples of innovation in the past, but also at future inno-
vations that can already be expected. Nuclear transfer aimed to
avoid the transmission of mitochondrial disease is one example
(Tachibana et al., 2009). The use of artificial gametes (created from
human embryonic or induced pluripotent stem cells), at first for
basic research and in the context of stem cell therapy, but eventually
perhaps also for reproduction, is another (Marques-Mari et al., 2009).
Responsibly introducing these new technologies will be a great chal-
lenge that the field cannot just leave to individual centres and prac-
titioners (Mertes and Pennings, 2009).
We think that ESHRE is especially equipped to take the lead here.
Doing so fits in with its existing commitment to responsible inno-
vation, as shown for instance in the case of PGS (Harper et al.,
2010). We are not proposing anything entirely new, however, we
think that this existing commitment can be strengthened by concrete
initiatives on several fronts.
First, building on elements already in place (like Task Force docu-
ments), it is important to further develop an explicit framework for
responsible innovation. This would serve not only as a point of refer-
ence for the field itself, but also demonstrate its commitment to being
accountable to patients and to society at large (O’Neill, 2002; Franklin
and Roberts, 2006).
Secondly, this framework needs to be filled in and adapted to tan-
gible fields of innovation. Thinking of the envisaged framework as
something that would engage different layers of the ESHRE commu-
nity, we see an important role here for the expertise accumulated
in ESHRE’s Special Interest Groups (SIGs), including the SIG for
Safety and Quality in Medically Assisted Reproduction. This should
lead to more concrete guidance with regard to issues such as when
preclinical studies are needed and of what sort, the level of (un)cer-
tainty at which the step to first applications in humans can be justified
and on the basis of what criteria, whether parallel animal or embryo
studies may still be useful after clinical introduction, how much evi-
dence about effectiveness and safety there must be before the label
of ‘experimental’ can be lifted, and how long-term follow-up studies
can be optimally designed to yield useful information.
Thirdly, the problem that really important research is often imposs-
ible because of lack of funds, leads to the question whether ESHRE can
do more to help overcoming this problem, either by direct
(co-)funding or through indirect ways of organising funding. Since an
increasingly important motive for evaluating assisted reproduction is
its public health impact, other societal actors: governments, public
health agencies, pharmaceutical industries and health insurance com-
panies can be asked to contribute to this as well. Patient organizations
can play a role in discussing the importance of participating in
follow-up research. Getting the required research off the ground
should be a joint responsibility of the field and of society as a whole.
Finally, ESHRE might use its influence to call upon society to take its
responsibility also with regard to proper regulation. One important
concern is that strict privacy regulations may hamper research using
health registries. Society should also be asked to refrain from or lift
laws and regulations that may sound impressive in terms of embryo
protection but that have the perverse effect of limiting the options
for preclinical safety research. Categorical bans are often a doubtful
sign of moral one-dimensionality. On this point the European Conven-
tion for Human Rights and Biomedicine needs to be changed.
Concluding remarks
We have called for a continuous and explicit commitment from the
field to the ideal of responsible innovation. An important further ques-
tion that we have not addressed but want to put on the agenda is how
to respond if IVF or specific applications (or their use in specific popu-
lations) turn out to lead to subtle adverse health effects such as a
somewhat higher risk for cancer or other adult diseases. Some may
think that assisted reproduction is only acceptable as long as it leads
to perfectly healthy children. In our view, this is untenable. IVF, or
some variant thereof, that leads to a happy child with a somewhat
higher chance of disease later in life may still be responsible treatment.
But inevitably, the question becomes what technology-related risks are
still acceptable, both in the light of the welfare of the future child and
from a public health perspective. Addressing such questions in a way
that confirms the commitment of the field to responsible innovation is
a requirement of accountability and a condition for trust.
Authors’ roles
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2010.
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